DBT’s BIRAC (est. 2012) announced expanded support for startups in pharma/biopharma via grants and interfaces. Includes new calls for monoclonal antibodies against Nipah virus. Trending: Indigenous manufacturing push, with ₹1,000 Cr RDI outlay for private R&D.